Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 75

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 8
Chunk 75
---
 recent significant business updates include the following: 

•Samraat Raha has been appointed President and Chief Executive Officer, effective April 30, 2025.

•Mark Verratti has been appointed Chief Operating Officer, effective April 30, 2025.

•Brian Donnelly has been appointed Chief Commercial Officer, effective May 1, 2025.

•In April 2025, new clinical data on the Precise MRD test in oligometastatic clear-cell Renal Cell Carcinoma was presented at the American Association for Cancer Research.

Results of Operations for the Three Months Ended March 31, 2025 and 2024 

The results of operations for the three months ended March 31, 2025 and 2024 are discussed below.  

Revenue

The following table summarizes revenue changes in our core product categories:

Three months ended March 31,% of Total Revenue(in millions)20252024Change20252024Hereditary Cancer$86.3 $88.1 $(1.8)44%44%Tumor Profiling29.3 30.9 (1.6)15%15%Prenatal49.3 44.3 5.0 25%22%Pharmacogenomics31.0 38.9 (7.9)16%19%Total revenue$195.9 $202.2 $(6.3)100%100%

The following table summarizes volume changes in our core product categories:

Three months ended March 31,(in thousands)20252024% ChangeProduct volumes:Hereditary Cancer73 71 3%Tumor Profiling12 14 (14)%Prenatal173 172 1%Pharmacogenomics127 124 2%Total385 381 1%

Revenue decreased $6.3 million for the three months ended March 31, 2025 compared to the same period in the prior year. For the three months ended March 31, 2024, the Company recognized $7.0 million of revenue for tests in which the performance obligation was met in a prior period, including $3.0 million in revenue due to a retroactive coverage change by a payor for one of its prenatal products. For the three months ended March 31, 2025, revenue for tests in which the performance obligation was met in a prior period was immaterial. 

Pharmacogenomics revenue decreased $7.9 million for the three